Table 1.
Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 315 JIA patients
| Systemic | Oligoarthritis | RF− poly-arthritis | RF+ poly-arthritis | Psoriatic arthritis | Enthesitis related arthritis | Undifferentiated arthritis | All JIA patients | Healthy | |
|---|---|---|---|---|---|---|---|---|---|
| N = 16 | N = 98 | N = 107 | N = 16 | N = 28 | N = 34 | N = 16 | N = 315 | N = 98 | |
| Female | 7 (43.8%) | 79 (80.6%) | 94 (87.9%) | 14 (87.5%) | 18 (64.3%) | 15 (44.1%) | 10 (62.5%) | 237 (75.2%)** | 49 (50%)# |
| Age at visit | 10.8 (7.9–12.4) | 11.7 (8–15.6) | 13.5 (10.9–16.8) | 15.6 (13.3–16.8) | 14.2 (11–16.5) | 14.5 (10.4–15.9) | 15.1 (13.7–16.8) | 13.5 (10.1–16.1)* | 12 (8.1–15.4)* |
| Age at onset | 5.5 (2.7–10.7) | 4 (2.4–8.7) | 7.4 (3.3–11) | 11.5 (9–13.2) | 9.2 (6–12.3) | 10.4 (6.8–12.5) | 9.5 (8.3–12.9) | 7.8 (3.3–11.1)* | |
| Disease duration | 3.4 (1.6–6.1) | 4.9 (1.6–7.9) | 4.2 (2–9.3) | 2.4 (1.7–6.5) | 3.9 (2.2–6.2) | 3 (1.7–6) | 4.3 (1.2–6) | 4.1 (1.8–7.9) | |
| ESR | 11 (5–18) | 6 (4–12) | 7 (5–13) | 7 (6–20) | 6.5 (3–10.5) | 6.5 (2–14) | 9.5 (6–11) | 7 (4–13) | |
| MD VAS | 0 (0–0) | 0 (0–1) | 0 (0–2) | 1 (0–2) | 0 (0–2) | 1 (0–3) | 0.5 (0–3) | 0 (0–2)* | |
| No. swollen joints | 0 (0–0) | 0 (0–0) | 0 (0–1) | 0 (0–2) | 0 (0–0) | 0 (0–0) | 0 (0–1) | 0 (0–0)* | |
| No. joints with pain | 0 (0–0) | 0 (0–0) | 0 (0–1) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–1) | 0 (0–0) | |
| No. joints with LOM | 0 (0–0) | 0 (0–0) | 0 (0–2) | 0 (0–2) | 0 (0–2) | 0 (0–3) | 1 (0–1.5) | 0 (0–1)** | |
| No. active joints | 0 (0–0) | 0 (0–0) | 0 (0–1) | 0 (0–2) | 0 (0–0) | 0 (0–0) | 0 (0–1.5) | 0 (0–1)* | |
| Active systemic features | 2 (12.5%) | 2 (2%) | 1 (0.9%) | 0 (0%) | 1 (3.6%) | 0 (0%) | 0 (0%) | 6 (1.9%) | |
| ANA status | 0 (0%) | 2 (2%) | 3 (2.8%) | 0 (0%) | 2 (7.1%) | 0 (0%) | 1 (6.3%) | 8 (2.5%) | |
| Uveitis | 1 (6.3%) | 21/97 (21.6%) | 9/105 (8.6%) | 0 (0%) | 3 (10.7%) | 1/33 (3%) | 1 (6.3%) | 36/311 (11.6%)* | |
| PF Total Score | 1 (0–4) | 0 (0–2) | 1 (0–4) | 0 (0–3) | 1 (0–4) | 2 (0–7) | 0 (0–4) | 1 (0–4) | 0 (0–0)# |
| Pain VAS | 0.5 (0–2) | 1 (0–3.5) | 1 (0–2.5) | 0.3 (0–1.5) | 1 (0–3) | 3 (1–5) | 0 (0–3.5) | 1 (0–3)* | 0 (0–0)# |
| Disease Activity VAS | 0.5 (0–2.5) | 0.5 (0–4) | 1 (0–3) | 0.8 (0–5) | 1 (0–5.5) | 3 (1–7) | 1 (0–3) | 1 (0–4) | |
| Well-being VAS | 0 (0–2) | 0.5 (0–2.5) | 0.5 (0–2) | 0 (0–3) | 1 (0–2.5) | 2 (1–3.5) | 1 (0–3.5) | 0.5 (0–3)* | |
| HRQoL PhH | 0 (0–5) | 1 (0–4) | 1 (0–4) | 1 (0–1) | 2 (1–4) | 3 (2–5) | 0 (0–2) | 1 (0–4)* | 0 (0–0)# |
| HRQoL PsH | 0 (0–2) | 0 (0–3) | 1 (0–3) | 0.5 (0–2) | 2 (0–3) | 2 (1–4) | 1 (0–3) | 1 (0–3) | 0 (0–0)# |
| HRQoL Total Score | 0 (0–6) | 2 (0–6) | 3 (1–7) | 2 (0–5) | 3 (2–7) | 6 (3–9) | 2 (0–5) | 3 (1–7)* | 0 (0–1)# |
| Pain/swell. in > 1 joint | 4 (26.7%) | 44 (50.6%) | 50 (55.6%) | 5 (35.7%) | 13 (56.5%) | 27 (81.8%) | 7 (46.7%) | 150 (54.2%)* | 2 (2.2%)# |
| Morning stiffness > 15 min | 3 (20%) | 20 (23%) | 21 (23.3%) | 3 (21.4%) | 4 (17.4%) | 22 (66.7%) | 1 (6.7%) | 74 (26.7%)* | 0 (0%)# |
| Subjective remission | 4 (26.7%) | 50 (57.5%) | 49 (54.4%) | 6 (42.9%) | 12 (52.2%) | 26 (78.8%) | 9 (60%) | 156 (56.3%)* | |
| In treatment | 13 (86.7%) | 59 (67.8%) | 80 (88.9%) | 13 (92.9%) | 20 (87%) | 27 (81.8%) | 10 (66.7%) | 222 (80.1%) | |
| Reporting side effects | 2/13 (15.4%) | 19/59 (32.2%) | 24/80 (30%) | 3/13 (23.1%) | 9/20 (45%) | 8/27 (29.6%) | 1/10 (10%) | 66/222 (29.7%) | |
| Taking medication regularly | 12/13 (92.3%) | 57/59 (96.6%) | 67/80 (83.8%) | 12/13 (92.3%) | 18/20 (90%) | 26/27 (96.3%) | 7/9 (77.8%) | 199/221 (90%) | |
| With problems attending school | 1/8 (12.5%) | 7/59 (11.9%) | 10/63 (15.9%) | 1/13 (7.7%) | 3/17 (17.6%) | 6/20 (30%) | 1/14 (7.1%) | 29/194 (14.9%) | 0 (0%)** |
| Satisfied with disease outcome | 13 (86.7%) | 70 (80.5%) | 71 (78.9%) | 11 (78.6%) | 18 (78.3%) | 21 (63.6%) | 11 (73.3%) | 215 (77.6%) |
Data related to the JAMAR refers to the 277 JIA patients and to the 92 healthy subjects for whom the questionnaire has been completed by the parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS visual analogue scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001